Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($0.15), $0.62 better than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.